Checked
Biomarin Pharmaceutical Inc
Nasdaq: BMRN · Pharmaceutical Preparations · Novato, CA
- Revenue
- $3.22B
- +12.9% vs. prior year
- Net income
- $348.9M
- 10.8% net margin
- Total assets
- $7.59B
- Diluted EPS
- $1.80
Company details
As reported to the SEC
- SEC CIK
- 1048477
- Stock
- Nasdaq: BMRN
- Legal Entity Identifier (LEI)
- NSLL8ITTRR0J5HEMR848
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 105 Digital Drive, Novato, CA 94949
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Phone
- (415) 506-6700
- Employer ID (EIN)
- 68-0397820
- Last annual report
- 02/26/2026
- Last quarterly report
- 08/06/2026
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.1B | $1.85B |
| Operating income | $409.5M | $484.2M | $185.8M | $161M | -$82.34M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | -$64.08M |
| Diluted earnings per share | $1.80 | $2.21 | $0.87 | $0.75 | -$0.35 |
| Research and development | $921.9M | $747.2M | $746.8M | $649.6M | $628.8M |
| Total assets | $7.59B | $6.99B | $6.84B | $6.38B | $6B |
| Total liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B |
| Shareholders' equity | $6.09B | $5.66B | $4.95B | $4.6B | $4.27B |
| Cash and cash equivalents | $1.31B | $942.8M | $755.1M | $724.5M | $587.3M |
| Cash from operations | $828M | $572.8M | $159.3M | $175.9M | $304.5M |
| Capital expenditures | $103M | $85.42M | $96.69M | $121M | $95.58M |
Federal and state records filed under the name Biomarin Pharmaceutical Inc
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| BioMarin Pharmaceutical Inc.Novato, CA | 7 | 2 |
Layoff notices (WARN)
1 notice covering 117 workers, filed with state labor departments
| Location | Notice date | Workers |
|---|---|---|
| Novato, CAlayoff | 09/24/2026 | 117 |
Subsidiaries
2 companies that Biomarin Pharmaceutical Inc owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| BIOMARIN INTERNATIONAL LIMITED | GLEIF, SEC 10-K |
| BioMarin Commercial Ltd | SEC 10-K |
Recent filings
121 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
44 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Biomarin Pharmaceutical Inc in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Biomarin Pharmaceutical Inc's CIK number?
- Biomarin Pharmaceutical Inc's SEC Central Index Key (CIK) is 1048477.
- What is Biomarin Pharmaceutical Inc's stock ticker?
- Biomarin Pharmaceutical Inc trades as Nasdaq: BMRN.
- What was Biomarin Pharmaceutical Inc's revenue?
- Biomarin Pharmaceutical Inc reported revenue of $3.22B for the fiscal year ended Dec 31, 2025, +12.9% from the year before.
- When does Biomarin Pharmaceutical Inc's fiscal year end?
- Biomarin Pharmaceutical Inc's fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Biomarin Pharmaceutical Inc headquartered?
- Biomarin Pharmaceutical Inc's principal executive office on file with the SEC is in Novato, CA.
- What companies does Biomarin Pharmaceutical Inc own?
- Biomarin Pharmaceutical Inc lists 2 subsidiaries in its SEC filings and other public records, including BIOMARIN INTERNATIONAL LIMITED, BioMarin Commercial Ltd.
- Does Biomarin Pharmaceutical Inc sponsor H-1B visas?
- Department of Labor records show 7 certified H-1B filings and 2 certified PERM filings under the name Biomarin Pharmaceutical Inc.
- Has Biomarin Pharmaceutical Inc filed layoff notices?
- State labor departments list 1 WARN layoff notice under the name Biomarin Pharmaceutical Inc, covering 117 workers. The latest is dated Sep 24, 2026.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026